Home Categories API Lacosamide
A5287812

Lacosamide , 98% , 175481-36-4

CAS NO.:175481-36-4

Empirical Formula: C13H18N2O3

Molecular Weight: 250.29

MDL number: MFCD08272557

EINECS: 605-756-0

Pack Size Price Stock Quantity
10MG RMB388.00 In Stock
1g RMB508.80 In Stock
25MG RMB1008.00 In Stock
50MG RMB1094.40 In Stock
others     Enquire
Update time: 2022-07-08

PRODUCT Properties

Melting point: 141-143?C
alpha  D23 +16.0° (c = 1 in CH3OH)
Boiling point: 536.4±50.0 °C(Predicted)
Density  1.120±0.06 g/cm3(Predicted)
Flash point: 2℃
storage temp.  Refrigerator
solubility  DMF: 20 mg/ml; DMSO: 20 mg/ml; Ethanol: 20 mg/ml; PBS (pH 7.2): 2 mg/ml
form  A crystalline solid
pka 14.19±0.46(Predicted)
color  white to beige
optical activity [α]/D 13 to 18° (C=0.5g/100mL, MeOH)
InChI InChI=1S/C13H18N2O3/c1-10(16)15-12(9-18-2)13(17)14-8-11-6-4-3-5-7-11/h3-7,12H,8-9H2,1-2H3,(H,14,17)(H,15,16)/t12-/m1/s1
InChIKey VPPJLAIAVCUEMN-GFCCVEGCSA-N
SMILES C(NCC1=CC=CC=C1)(=O)[C@H](NC(C)=O)COC
CAS DataBase Reference 175481-36-4

Description and Uses

Although epilepsy is a neurological disorder with varying etiology and severity, the common feature is unprovoked, recurring seizures. Whether classified as generalized, involving both cerebral hemispheres, or partial with only localized portions of brain participation at onset, effective treatment relies on accurate assessment of syndrome type to optimally decrease the frequency, duration, and severity of seizures. The latest weapon against partial onset epilepsy is lacosamide, formerly known as harkoseride and erlosamide. The data also indicate that lacosamide binds to collapsing response mediator protein 2 (CRMP2); CRMP2 is involved in neuronal differentiation, control of axonal outgrowth, and possibly epileptogenesis. Furthermore, lacosamide is heralded as having a dual mode of action as it has also displayed efficacy against diabetic neuropathy, possibly as a result of stabilization of neuronal hyperexcitability. Currently,lacosamide is approved as adjunctive treatment of partial onset seizures in patients 17 years or older and is in development as a monotherapy for epilepsy and for neuropathic pain.

A potent anticonvulsant.

Safety

Symbol(GHS) 
GHS02,GHS07
Signal word  Danger
Hazard statements  H225-H302+H312+H332-H319
Precautionary statements  P210-P280-P305+P351+P338
Hazard Codes  F,Xn
Risk Statements  11-20/21/22-36
Safety Statements  16-26-36/37
RIDADR  UN 1648 3 / PGII
WGK Germany  2
HS Code  2924296000

RELATED PRODUCTS